LAVAL, QC, Aug. 24 /CNW/ - BioSyntech, Inc. (TSX: BSY), a biotechnology
company developing biotherapeutic thermogels for regenerative medicine, today
announced it has appointed two additional members to its Board of Directors,
Mr. André Archimbaud and Ms. Jeanne Bertonis, Chief Executive Officer for
BioSyntech. Mr. Archimbaud will serve as Chairman of the Board.
"Mr. Archimbaud brings his considerable experience in the life sciences
and pharmaceutical sectors to his role of Chairman of the Board of Directors.
Ms. Bertonis, as our newly appointed CEO, will now expand her role to include
this board position," said Dr. Joyce Tsang, Director and Chair of the
Governance Committee of BioSyntech. "These two individuals are experienced
Board members and the counsel of both Mr. Archimbaud and Ms. Bertonis will be
invaluable in helping BioSyntech to realize its corporate objectives."
Mr. Archimbaud most recently served as Senior Vice President, Life
Sciences for the Société Générale de Financement (SGF) du Québec, a
government-owned investment entity contributing to the development of life
sciences both locally and internationally. Prior to SGF, Mr. Archimbaud was
the President and Chief Executive Officer of Vancouver-based Kinetek
Pharmaceuticals Inc., a biotech start-up recognized for its expertise in the
field of molecular biology applied to oncology. Mr. Archimbaud also held
progressively senior roles in sales, marketing, business development and
licensing in his 20 years with Ipsen Beaufour, a European pharmaceutical
BioSyntech also announced that Dr. Matthew Shive, former Chief Scientific
Officer of BioSyntech, has been retained as a consultant to Company.
BioSyntech is a medical device company specialized in the development,
manufacturing and commercialization of advanced biotherapeutic thermogels for
regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's
platform technology is a family of hydrogels called BST-Gel(R), some of which
are liquid at low temperature and solid at human body temperature. These gels
can be injected or applied to a specific local site and offer beneficial
properties for the local repair of damaged tissue such as cartilage, bone and
chronic wounds and provide the benefit of avoiding invasive surgery. For
additional information, visit www.biosyntech.com.
This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the adequacy, timing, and results of our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, the success of research and
development programs, reliance on subcontractors and key personnel, and other
risks and uncertainties detailed from time-to-time in our filings with the
Canadian securities commissions.
Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information about (i) the material factors that could cause actual results to
differ materially from the conclusion, forecast or projection in the
forward-looking information, and (ii) the material factors or assumptions that
were applied in drawing a conclusion or making a forecast or projection as
reflected in the forward-looking information, is contained in the Company's
annual report and other documents filed from time to time with the Canadian
securities commissions which are available at www.sedar.com. These statements
speak only as of the date they are made, and we assume no obligation to revise
such statements as a result of any event, circumstance or otherwise, except in
accordance with law.
For further information:
For further information: James Smith, The Equicom Group, (416) 815-0700